Transthyretin-Associated Amyloidoses Outcome Survey (THAOS) (THAOS)
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin-associated amyloidoses (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate.
The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.
Other: None. Observational Study.
|Study Design:||Observational Model: Other
Time Perspective: Prospective
|Official Title:||Transthyretin-associated Amyloidosis Outcomes Survey (Thaos): A Global, Multi-center, Longitudinal, Observational Survey Of Patients With Documented Transthyretin (Ttr) Mutations Or Wild-type Ttr Amyloidosis|
- The objectives of THAOS are to describe the population of patients affected with TTR amyloidoses and to enhance the understanding of the disease natural history, including the variability and progression of the hereditary and acquired forms of disease. [ Time Frame: Dec 2007 to June 2021 ]
Biospecimen Retention: Samples With DNA
|Actual Study Start Date:||July 27, 2007|
|Estimated Study Completion Date:||June 16, 2021|
|Estimated Primary Completion Date:||June 16, 2021 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00628745
|Contact: Pfizer CT.gov Call Center||1-800-718-1021|
Show 97 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|